Co-Authors
This is a "connection" page, showing publications co-authored by Pierluigi Viale and Francesco De Rosa.
Connection Strength
0.656
-
The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Rev Anti Infect Ther. 2021 09; 19(9):1125-1134.
Score: 0.234
-
Rationale for Polyclonal Intravenous Immunoglobulin Adjunctive Therapy in COVID-19 Patients: Report of a Structured Multidisciplinary Consensus. J Clin Med. 2021 Aug 08; 10(16).
Score: 0.060
-
Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infect Dis Ther. 2021 Dec; 10(4):1837-1885.
Score: 0.060
-
Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study. J Clin Med. 2021 Feb 03; 10(4).
Score: 0.058
-
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clin Microbiol Infect. 2020 Jul; 26(7):880-894.
Score: 0.055
-
Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. J Infect. 2019 08; 79(2):130-138.
Score: 0.052
-
Ceftolozane/tazobactam: place in therapy. Expert Rev Anti Infect Ther. 2018 04; 16(4):307-320.
Score: 0.047
-
Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents. 2018 Feb; 51(2):244-248.
Score: 0.046
-
Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. J Chemother. 2017 Aug; 29(4):197-214.
Score: 0.044